C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

OBJECTIVE: On-treatment levels of high sensitivity C-reactive protein (hsCRP) in statin-treated patients predict plaque progression and the prospective risk of atherosclerotic cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors produce additional LDL-C lowering, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Adam J., Puri, Rishi, Brennan, Danielle M., Anderson, Todd J., Cho, Leslie, Ballantyne, Christie M., Kastelein, John JP., Koenig, Wolfgang, Kassahun, Helina, Somaratne, Ransi M., Wasserman, Scott M., Nissen, Steven E., Nicholls, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315612/
https://www.ncbi.nlm.nih.gov/pubmed/34327467
http://dx.doi.org/10.1016/j.ajpc.2020.100091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315612/
https://www.ncbi.nlm.nih.gov/pubmed/34327467
http://dx.doi.org/10.1016/j.ajpc.2020.100091

Ejemplares similares